The study is to evaluate the efficacy and safety of evobrutinib administered orally twice
daily versus Teriflunomide (Aubagio), administered orally once daily in participants with
Relapsing Multiple Sclerosis (RMS).
Relapsing Multiple Sclerosis
Placebo (match to Teriflunomide),
Placebo (match to Evobrutinib)
Clinical Study Identifier
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.